Kounis Syndrome: Epinephrine's Coronary Risk Versus Its Role in Anaphylaxis
A man with a coronary stent develops new ST-elevation mid-resuscitation for contrast anaphylaxis. The drug already running through his IV may be treating one problem and provoking the other at the same time.
E.V., a 66-year-old man with a coronary stent placed four years ago for stable disease, came in today for a routine contrast CT and was in anaphylaxis within minutes of the injection — hives across his torso, a blood pressure that dropped to 82 over 50, audible wheezing. Mid-resuscitation, with epinephrine already on board, he developed crushing chest pain, and the monitor showed new ST-elevation in the inferior leads; a troponin drawn shortly after came back mildly elevated. He walks three miles most mornings with his wife, has never had chest pain before today, and his most recent stress test, performed two years ago as part of routine cardiology follow-up, was unremarkable — a clean study and two subsequent years without angina is not the background a spontaneous inferior infarction usually emerges from, which is precisely what makes the ST-elevation appearing mid-resuscitation for a contrast reaction read as part of that reaction rather than a coincidence keeping bad company. The team recognizes the picture as Kounis syndrome — a coronary event triggered by the same mast cell mediators driving his anaphylaxis, not a coincidental second problem — but recognizing the mechanism doesn't resolve what happens next with the drug already running through his IV.
Epinephrine is the unambiguous first-line treatment for anaphylaxis, including his — hypotension this severe, from a reaction this active, is not a scenario where withholding it is a neutral choice. But epinephrine's own alpha-1-mediated vasoconstriction, the same effect propping up his blood pressure, acts on coronary vessels too, and the literature on this exact syndrome — a coronary event caused by an allergic reaction, first described by Kounis and Zavras — has repeatedly documented epinephrine itself appearing to worsen the coronary component in a real subset of cases, an uncomfortable irony where the drug treating one arm of the same process may be aggravating the other. What the room actually has to decide, in real time, is not whether epinephrine is indicated in principle, but how much of it, by what route, and how quickly cardiology needs to be at the bedside alongside it.
At the bedside
His anaphylaxis is still active — he's hypotensive, he's wheezing, hives are still spreading. Every guideline I've ever trained under treats withholding epinephrine in this picture as the dangerous default, and for good reason: delayed or withheld epinephrine is a recurring, documented cause of preventable anaphylaxis death. The coronary finding is real and concerning, but I don't think it changes what's killing him faster right now.
I'm not arguing his anaphylaxis isn't real or serious. I'm pointing out that Kounis syndrome's own literature — going back to Kounis and Zavras's original description and repeated in case series since — documents epinephrine itself appearing to worsen the coronary component in a real subset of these exact cases, through the same alpha-1 vasoconstriction that's holding his pressure up. He has a new ST-elevation and a rising troponin. That's an independently life-threatening process now, not a footnote to the allergic one, and I'd rather maximize fluids, antihistamines, and steroids first and reserve epinephrine for if he becomes refractory.
I take the guideline point seriously. I don't think it was written with a simultaneous acute coronary event in the same patient in mind.
I don't think this is actually give-or-withhold. A standard intramuscular dose of epinephrine and an escalated or IV dose behave differently in terms of how much coronary vasoconstriction they produce, and his anaphylaxis severity — real hypotension, ongoing reaction — does meet the bar for standard-dose treatment regardless of the coronary finding. Give the standard IM dose, not more, while cardiology comes to the bedside now rather than after we've decided whether epinephrine is allowed. Both processes plausibly trace to the same mast cell mediator surge — treating the allergic reaction promptly and appropriately may genuinely help the coronary picture rather than only threatening it.
Agreed: standard intramuscular epinephrine dose given (not escalated, not IV) alongside aggressive IV fluids, H1/H2 antihistamines, and glucocorticoids; cardiology activated urgently at the bedside; his ST-elevation resolves over the next twenty minutes as his hemodynamics stabilize, without requiring emergent catheterization, and troponin peaks modestly before trending down.
Not agreed, and left open rather than smoothed over:
The cardiologist leans toward a true Kounis vasospastic mechanism given the temporal pattern with the allergic reaction.
The emergency medicine physician isn't convinced distinguishing that from demand ischemia changes anything actionable today.